Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis.
about
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)Mevalonate Pathway Blockade, Mitochondrial Dysfunction and Autophagy: A Possible LinkMonogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signalsWhy not treat human cancer with interleukin-1 blockade?Caspase functions in cell death and disease.Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses.An update on autoinflammatory diseasesMonogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis.Blocking interleukin-1 in rheumatic diseasesInterleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesAn expanding role for interleukin-1 blockade from gout to cancer.Autoinflammation: translating mechanism to therapy.Therapy of autoinflammatory syndromes.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Inflammasome-mediated autoinflammatory disorders.Schnitzler's syndrome: successful treatment with anakinra.Biological treatments: new weapons in the management of monogenic autoinflammatory disordersDivergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.Nummular keratopathy in a patient with Hyper-IgD Syndrome.Treating inflammation by blocking interleukin-1 in humans.Inflammasome and IL-1beta-mediated disordersAutoinflammatory syndromes: diagnosis and management.The emerging role of interleukin-1β in autoinflammatory diseases.The NLRP3 inflammasome in health and disease: the good, the bad and the ugly.Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency.The effect of clodronate on a mevalonate kinase deficiency cellular model.Temperature and drug treatments in mevalonate kinase deficiency: an ex vivo study.Clinical genetic testing of periodic fever syndromesOpen-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome.Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome.A case of hyperimmunoglobulinemia d syndrome successfully treated with canakinumab.Anti-interleukin 6 receptor therapy for hyper-IgD syndrome.PW02-020 - Colitis revealing mevalonate kinase deficiency.Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency.
P2860
Q24631660-96ABE776-0E97-4A94-8F09-B027DC298A56Q26799973-103617E9-E2DC-4996-9B01-47C8354ADCB4Q33798590-DCB76FEF-043C-4AD6-8FA9-0E797A5F8728Q33833871-1FF1C193-A2DF-4827-92F6-F6FBF9CDB355Q34336335-A2C17346-D01A-4811-937D-6FBBF3F191C8Q34369278-649CCD72-68A8-43B0-8CE0-F6E583C612F6Q34380526-B8F7A1C7-F2A7-4C2C-A3E6-7FAF71177A4AQ34489840-140391D4-2E8B-477A-B826-13035F824DE6Q34822708-425DC60A-65F1-46C2-A947-33604BC2F696Q35133812-095B8BAF-6190-4520-AA44-03950B8E7725Q35219001-275D16CC-56B2-4C65-8C05-58B43A985BB7Q35558406-1E1989AB-29BE-48EB-9328-F739428CCBEEQ35868028-1AD794C1-6FCF-414B-BC9F-D16D6240BB2EQ36816872-30AC8387-3CC6-4A80-836A-3F9EBF128835Q36829403-45A3E532-C24E-4873-AB8C-DF02B5181D63Q36903081-F8454A21-E0FC-49CF-BD0C-7B0D775F76C7Q37077564-458E41C6-05FF-4BCD-AE3D-D95FEC1188B0Q37259317-04FEB4E0-5F06-4D1D-B5E4-B4F700D74F99Q37270409-B67B0729-4642-44FE-8542-E845E9361B06Q37572943-9D05E0C5-4E50-448B-9A14-96D5B451EC58Q37636664-C71ECE67-3A3E-4022-BEBC-1124D11E1C77Q37738096-791AC076-EC6E-438E-83B7-6A152528FD3FQ37784856-069FD152-3B25-4A0C-9C73-C6D48D44DA53Q37897494-ABA397E1-4D13-4A80-BEA9-7359C8FC3582Q37901519-C08311D6-1CA5-4DD1-A243-C2F9FA7560D3Q37979862-3DBA27E5-AD92-41BA-85C9-6183D260226EQ38871606-45B94F54-8F71-45DB-B26E-62109E60070DQ39304480-66109DE8-60D7-4E2A-AF24-AAD70EA7FC5DQ39343545-5C2375CC-050C-467D-929F-D4EBB7C48840Q39452889-8666DF02-EAAA-49CF-BF5B-FFB16D5D7136Q40057989-ECC0EDA8-E199-4694-A8B0-AED73503AAA8Q40371224-4E307834-AFBF-4B41-9073-D028EFE7DB6EQ40640510-B88117EC-DE41-4670-9630-D6FCF390CE43Q43184639-E311823D-119D-429E-A74C-FF989C7A320AQ46060551-0C60110C-D5A9-4169-8210-7C1EB3B78B2DQ46662065-DE0B8638-7727-4E55-B791-46220E1F732A
P2860
Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Anakinra is safe and effective ...... ome-associated febrile crisis.
@en
type
label
Anakinra is safe and effective ...... ome-associated febrile crisis.
@en
prefLabel
Anakinra is safe and effective ...... ome-associated febrile crisis.
@en
P2093
P1476
Anakinra is safe and effective ...... ome-associated febrile crisis.
@en
P2093
Cailliez M
Kone-Paut I
Rousset-Rouvière C
Tsimaratos M
P2888
P356
10.1007/S10545-006-0408-7
P577
2006-11-10T00:00:00Z
P6179
1010533983